Metabolic Peptides
Amycretin (Zenagamtide) 2026: Trial Data, Oral vs Injectable Dosing & Comparison to Retatrutide, CagriSema and Eloralintide
Michael Court
October 5, 2026
7 min read
Novo Nordisk's amycretin (zenagamtide) is a single-molecule GLP-1/amylin agonist now in Phase 3. See the Lancet trial data, ADA 2026 diabetes results, trial dosing, and how it compares with retatrutide, tirzepatide and CagriSema.